09:40 AM EST - Microbix Biosystems Inc. : And Labquality Oy (Labquality), announce a novel external quality assessment program to help ensure clinical laboratories accurately identify head and neck cancers associated with cancer-causing strains of Human Papilloma Virus. Labquality is introducing this novel EQA scheme at the 2025 meeting of the European Society for Clinical Virology in Thessaloniki, Greece 17-20 September. Microbix Biosystems Inc.
shares T.MBX are trading unchanged at $0.23.
